Grygier, P.; Pustelny, K.; Nowak, J.; Golik, P.; Popowicz, G.M. et al.: Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. In: Journal of Medicinal Chemistry (formerly: Journal of Medicinal and Pharmaceutical Chemistry) 66 (2023), Nr. 6, S. 4009-4024. DOI: https://doi.org/10.1021/acs.jmedchem.2c01887
Abstract: | |
A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer’s disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for studying the effect of the DYRK1A/GSK3β kinase system in disease biology and possible line extension. Motivated by the dual inhibition of these kinases, we solved and analyzed the crystal structures of DYRK1A and GSK3β with CX-4945. We built a quantum-chemistry-based model to rationalize the compound affinity for CK2α, DYRK1A, and GSK3β kinases. Our calculations identified a key element for CK2α’s subnanomolar affinity to CX-4945. The methodology is expandable to other kinase selectivity modeling. We show that the inhibitor limits DYRK1A- and GSK3β-mediated cyclin D1 phosphorylation and reduces kinase-mediated NFAT signaling in the cell. Given the CX-4945’s clinical and pharmacological profile, this inhibitory activity makes it an interesting candidate with potential for application in additional disease areas. | |
License of this version: | CC BY 4.0 Unported |
Document Type: | Article |
Publishing status: | publishedVersion |
Issue Date: | 2023 |
Appears in Collections: | Forschungszentren |
pos. | country | downloads | ||
---|---|---|---|---|
total | perc. | |||
1 | ![]() |
Germany | 12 | 48.00% |
2 | ![]() |
United States | 9 | 36.00% |
3 | ![]() |
Syrian Arab Republic | 1 | 4.00% |
4 | ![]() |
Poland | 1 | 4.00% |
5 | ![]() |
China | 1 | 4.00% |
6 | ![]() |
Chile | 1 | 4.00% |
Hinweis
Zur Erhebung der Downloadstatistiken kommen entsprechend dem „COUNTER Code of Practice for e-Resources“ international anerkannte Regeln und Normen zur Anwendung. COUNTER ist eine internationale Non-Profit-Organisation, in der Bibliotheksverbände, Datenbankanbieter und Verlage gemeinsam an Standards zur Erhebung, Speicherung und Verarbeitung von Nutzungsdaten elektronischer Ressourcen arbeiten, welche so Objektivität und Vergleichbarkeit gewährleisten sollen. Es werden hierbei ausschließlich Zugriffe auf die entsprechenden Volltexte ausgewertet, keine Aufrufe der Website an sich.